Staging and profiling in addication;Stagering en profilering bij verslaving

Tijdschrift voor Psychiatrie

Volumn 54, Issue 11, 2012, Pages 941-948

  Van Den Brink, Wim ^a   Schippers, G M ^a  

^a AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

Addiction; Dependency; DSM 5; Profiling; Staging

Indexed keywords

ADDICTION; ARTICLE; DISEASE CLASSIFICATION; ENDOPHENOTYPE; HUMAN; MEDICAL LITERATURE; NEUROBIOLOGY; ONCOLOGY; PHENOTYPE;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; PROGNOSIS; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84869478364     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. American Psychiatric Association. DSM-5 development. APA; 2011. http://www.dsm5.org
2. Beekman AT, van Os J, van Marie H, van Harten PN. Stagering en profilering van psychiatrische stoornis. Tijdschr Psychiatr 2012; 54: 915-20.
3. Brink W van den. Evidence-based Pharmacological Treatment of Substance use Disorders and Pathological Gambling. Curr Drug Abuse Rev 2011; 5: 3-31.
4. Bruijn C de, van den Brink W, de Graaf R, Vollebergh WA. The three year course of alcohol use disorders in the general population: DSM-IV, ICD-10 and the craving withdrawal model. Addiction 2006; 101: 385-92. (Pubitemid 43344821)
5. Cowherd SM. Tumor staging and grading: a primer. Methods Mol Biol 2012; 823: 1-18.
6. Emmelkamp P, Vedel E. Alcohol- en drugsverslaving: een gids voor effectief vgebleken behandelingen. Amsterdam: Nieuwezijds; 2007.
7. Kiefer F, Witt SH, Frank J, Richrer A, Treutlein J, Lemenaget T, e.a. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamptosate. Pharmacogenomics J 2011; 11: 368-74.
8. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35: 217-38.
9. Leshner AI. Addiction is a brain disease, and it matters. Science 1997; 278: 45-7. (Pubitemid 27446268)
10. Merkx MJ, Schippers GM, Koeter MJ, Vuijk PJ, Oudejans S, de Vries CC, e.a. Allocation of substance use disorder patients to appropriate levels of care: feasibility of matching guidelines in routine practice in Dutch treatment centres. Addiction 2007; 102: 466-74.
11. Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, e.a. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 2009; 14: 328-37.
12. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, e.a. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28: 1546-52.
13. Pedersen MU, Hesse M. A simple risk scoring system for prediction of relapse after inpatient alcohol treatment. Am J Addict 2009; 18: 488-93.
14. Rohsenow DJ, Miranda R Jr, McGeary JE, Monti PM. Family history and antisocial traits moderate nalttexone's effects on heavy drinking in alcoholics. Exp Clin Psychopharmacol 2007; 15: 272-81. (Pubitemid 47445255)
15. Schippers GM, Broekman TG, Buchholz A, Koeter MW, van den Brink W. Measurements in the Addictions fot Triage and Evaluation (MATE): an instrument based on the World Health Organization family of international classifications. Addiction 2010; 105: 862-71.
16. UICC. TNM classification of malignant turnouts. 7de druk. Chichester: Wiley-Blackwell; 2010. http://www.uicc.org/resources/tnm
17. Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol 2009; 23: 660-71.